Bogliolo L, Crepaldi G, Caporali R
UOC Reumatologia,IRCCS Fondazione Policlinico S Matteo, Pavia, Università di Pavia.
Reumatismo. 2012 Jun 5;64(2):88-98. doi: 10.4081/reumatismo.2012.88.
In rheumatic diseases, biomarkers may serve as surrogate endpoints for diagnosis, prognosis, disease activity, therapeutic response and disease outcome. In recent years a great effort has been made to identify useful tools to establish early diagnosis, prognosis and therapeutic response especially in rheumatoid arthritis (RA). In psoriatic arthritis (PsA) serological biomarkers have been frequently borrowed from RA, but this approach have sometimes lead to inappropriate choices of biomarkers and incorrect conclusions. Furthermore, the heterogeneous spectrum of articular manifestation of PsA and the variable course of the disease can make diagnosis and prognosis difficult. Recently, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) identified two key areas for biomarkers development in psoriasis and PsA: the diagnosis of the articular disease in patients with psoriasis and the evaluation of joint damage in PsA. In this review we revised the currently available and the new potential markers for PsA, such as serum, genetic, cellular and histological biomarkers, clinical and imaging data, with particular attention on the prognostic aspect in order to identify progressive disease suitable for a more aggressive treatment.
在风湿性疾病中，生物标志物可作为诊断、预后、疾病活动度、治疗反应及疾病转归的替代终点。近年来，人们付出了巨大努力来寻找有用的工具，以实现早期诊断、预后评估及治疗反应监测，尤其是在类风湿关节炎（RA）方面。在银屑病关节炎（PsA）中，血清学生物标志物常借鉴自RA，但这种方法有时会导致生物标志物选择不当及得出错误结论。此外，PsA关节表现的异质性谱及疾病进程的多变性会使诊断和预后评估变得困难。最近，银屑病和银屑病关节炎研究与评估小组（GRAPPA）确定了银屑病和PsA生物标志物开发的两个关键领域：银屑病患者关节疾病的诊断以及PsA关节损伤的评估。在本综述中，我们回顾了目前可用的以及新的PsA潜在标志物，如血清、基因、细胞和组织生物标志物、临床和影像学数据，特别关注预后方面，以便识别适合更积极治疗的进展性疾病。
